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Abstract
Purpose Sebaceous carcinoma (SC) is a clinical masquerader of benign conditions resulting in significant eye morbidity,
sometimes leading to extensive surgical treatment including exenteration, and even mortality. Little is known about the genetic
or molecular basis of SC. This study identifies the involvement of Hedgehog (Hh) signaling in periocular SC.
Methods Fifteen patients with periocular SC patients were compared to 15 patients with eyelid nodular basal cell carcinoma
(nBCC; a known Hh tumor), alongside four normal individuals as a control for physiological Hh expression. Expression of
Patched 1 (PTCH1), Smoothened (SMO), and glioma-associated zinc transcription factors (Gli1 and Gli2) were assessed in
histological sections using immunohistochemistry and immunofluorescence (IF) techniques. Antibody specificity was verified
using Western-blot analysis of a Gli1 over-expressed cancer cell line, LNCaP-Gli1. Semi-quantification compared tumors and
control tissue using IF analysis by ImageJ software.
Results Expression of the Hh pathway was observed in SC for all four major components of the pathway. PTCH1, SMO, and
Gli2 were more significantly upregulated in SC (P < 0.01) compared to nBCC. Stromal expression of PTCH1 and Gli2 was
observed in SC (P < 0.01). In contrast, stromal expression of these proteins in nBCC was similar or down-regulated compared to
physiological Hh controls.
Conclusions The Hh signaling pathway is significantly more upregulated in periocular SC compared to nBCC, a known aberrant
Hh pathway tumor. Furthermore, the stroma of the SC demonstrated Hh upregulation, in particular Gli2, compared to nBCC.
Targeting of this pathway may be a potential treatment strategy for SC.
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Introduction
Sebaceous carcinoma (SC) is a rare, aggressive cancer that has
a predilection for the periorbital region, but can originate from
extraocular sites, albeit mainly within the head region [1].
Geographical variation is significant, with the incidence
around 0.41 per million in UK, 0.65 per 100,000 in Canada,
whereas in China it represents almost one-third of the malig-
nant eyelid workload and is second to basal cell carcinoma
(BCC) in frequency [2–4]. In Japan, one study found that the
rate of SC equaled that of BCC [5]. SC has two broad macro-
scopic presentations, namely nodular (local) or pagetoid
(spreading). Misdiagnosis is common, often labeled as a be-
nign chalazion in its nodular form or conjunctivitis in the
conjunctival, pagetoid type (Supplementary Fig. S1). Thus,
it is described as a masquerading lesion with delays in diag-
nosis often greater than a year. Pagetoid expansion of the skin
or conjunctiva carries a higher risk of orbital exenteration [6].
Despite aggressive treatment, there is a high recurrence rate
and metastasis often occurs via the lymphatics to the cervical
lymph nodes [7]. Mortality rates were once very high at 29%,
but there is a significant range depending on which treatment
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modality is employed and can be as good as 6% in a center of
excellence [8–10]. Prognosis depends on the size of the initial
tumor and margin removed with a higher risk of recurrence
seen with 1-3 mm margin versus 5 mm; however, achieving
such a margin if the tumor is within the orbit is almost impos-
sible [11, 12]. Staged excision using margin control may also
improve removal of the tumor.
Hedgehog (Hh) signaling is essential during embryogene-
sis, and is down-regulated in most adult cells with transient
expression in some adult tissues including brain, testis, and
hair follicle [13, 14]. Hh signaling occurs via a cell membrane
receptor complex that includes the proteins Patched (PTCH1)
and Smoothened (SMO). In the absence of a Hh signal,
PTCH1 inhibits the activation of SMO and subsequent down-
stream signaling. In the presence of Hh, the repressive action
of PTCH1 on SMO is removed and the downstream pathway
is mediated via the glioma-associated zinc transcription fac-
tors, Gli1 and Gli2, which translocate to the nucleus and acti-
vate Hh-target genes [15]. Pathological activation of Hh sig-
naling occurs in a variety of cancers, including BCC, prostate
cancer, upper gastrointestinal tumors, a subset of small cell
lung carcinoma and pancreatic ductal adenocarcinoma
(Supplementary Table S1) [16–20]. Genetic variants in Hh
signaling are seen in up to 90% of sporadic BCC and many
demonstrate Gli1 overexpression [19, 21].
The behavior of solid tumors is not restricted to the tumor
borders delineated on microscopy; the surrounding non-
malignant microenvironment, termed stroma, has been shown
to play a key role in local spread [22]. During embryogenesis,
Hh signaling plays an important role in communication be-
tween epithelial tissue and surrounding stroma in a number of
tissues in order to promote growth and differentiation of the
stroma. For instance, urogenital epithelium utilizes Hh signal-
ing to promote surrounding mesenchymal tissue to develop
into the prostate gland [23]. Reactivation of this paracrine
phenomenon of Hh signaling has been shown in prostate can-
cer stroma and the tumor regulates the proliferation of adja-
cent non-malignant epithelium [24]. Studies in ovarian cancer
have highlighted the importance of the changes in the stroma
that confer a poorer prognosis [22, 25] and the promotion of
local invasion in morphoeic BCC has been demonstrated by
modulating the stromal milieu [26]. In this study, we exam-
ined the role of the canonical Hh pathway in both the SC
tumor and surrounding apparently normal stroma by compar-
ing it to nodular BCC (nBCC), a known Hh implicated tumor.
Materials and methods
Subjects
This study obtained national ethics committee approval (REC
reference 14/NW/1080) and adhered to the tenets of the
Declaration of Helsinki. The research was designed as a
non-paired observational, case control study whereby SC
(the case) is compared to nBCC (the Hh tumor control).
Fifteen patients with SCwere included for comparison against
15 nBCC patients with a mean age of 68 and 73, years respec-
tively. All of the SC patients had non-metastatic disease, ten
nodular and five pagetoid, requiring wide excision or exenter-
ation as treatment. Only clearly defined SC or BCC on histol-
ogy were included using the Royal College of Pathologists,
UK dataset [27, 28]. The presence of any non-nodular BCC
subtype, and poorly differentiated SC where it was difficult to
identify adnexal sebaceous lineage, were also excluded from
the study. In addition, exclusion criteria included SC or BCC
individuals with metastasis and/or recurrence. Subjects were
seen at one center, Moorfields Eye Hospital.
Immunostaining procedure
Hematoxylin and eosin (H&E) staining was performed using
standard methods. 3–3′-diaminobenzidine (DAB) immuno-
staining of 5 μm formalin-fixed, paraffin-embedded (FFPE)
tissue sections was performed using a panel of commercially
available antibodies for the Hh pathway proteins including
PTCH1, SMO, Gli1, and Gli2 (Abcam, Cambridge, UK).
Conditions for individual antibodies are summarized in
Supplementary Table S2. Tissue sections were mounted on
slides, deparaffinized in xylene and then alcohol, followed
by treatment with the DAKO EnVision™FLEX+ System
(Dako, Glostrup, Denmark) [29]. Briefly, antigen retrieval
was performed using the DAKO PT LINK machine at 97°C
for 20 min under alkaline (pH 9.0) or acidic (pH 6.0) condi-
tions (Table S1). Endogenous peroxidase activity was blocked
using EnVision™FLEX peroxidase-blocking reagent. Tissue
was incubated with primary antibody for 30 min, followed by
incubation with a secondary antibody (Envision™FLEX/
HRP LINKER; 20 min) and then visualization of the
primary-secondary reaction with EnVision™FLEX substrate
working solution containing buffer and DAB (10 min).
Sections were sealed and covered using the automated
Thermo Clearview Coverslipper (Thermo Fisher Scientific
Inc., Waltham, MA, USA). Positive control tissue included
breast, brain, testes, and intestine for PTCH1, SMO, Gli1,
and Gli2, respectively. Negative controls involved all steps
excluding the primary antibody. Finally, sections were coun-
terstained with hematoxylin using the Gemini autostainer
(Thermo Fisher Scientific Inc., Waltham, MA, USA).
Immunofluorescence
Immunofluorescence was used for semi-quantitative analysis of
Hh pathway expression in SC in comparison to nBCC. FFPE
sections were cut (5 μm) and antigen retrieval carried out as
described above. Blocking of the sections occurred with 5%
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goat serum for 1 h followed by primary antibody staining as
mentioned. Secondary antibody staining utilized AlexaFluor-
568 (Invitrogen™, Life Technologies, Thermo Fisher
Scientific Inc., Waltham, MA, USA). Nuclei were counter-
stained with 4′,6-diamidino-2-phenylindole dihydrochloride
(DAPI; Sigma-Aldrich®MO, USA) at 1:1000 dilution to high-
light the number of cells present and aid accurate semi-quanti-
fication. Coverslips were placed using VECTASHIELD®
mounting medium (Vector Laboratories Inc., Burlingame,
CA, USA). Negative controls omitted the primary antibody.
Confocal microscopy and fluorescence signal
quantification
Immunofluorescence sections were examined using the Zeiss
LSM710 Meta confocal laser microscope (Carl Zeiss
Microscopy GmbH, Jena, Germany) and a ZEN configuration
tool (Carl Zeiss Microscopy GmbH, Jena, Germany), which is
digital image-processing software that produces an output TIFF
image. Negative control slides were used to remove back-
ground fluorescence and set up the acquisition conditions that
subsequently remained constant throughout the imaging pro-
cess. Images were taken at 200× magnification. Output TIFF
images were analyzed using ImageJ (http//imagej.nih.gov/ij) to
quantify antibody expression. For semi-quantification of anti-
body expression, fluorescence intensity was determined in re-
gions of interest (ROIs), ensuring a standardized area size
whilst containing the same number of nuclei (averaging 18
cells) as determined by the DAPI staining. Tumor was defined
as within the bulk of the tumor and at least 1 mm from the edge.
Stromawas defined as non-cancerous surrounding tissue within
2mmof the tumor edge. Furthermore, three separate ROIs were
taken for each area in each sample (i.e., three tumor ROIs and
three stroma ROIs in nBCC or SC samples) to obtain a mean
signal for comparison.
Western blotting for antibody validation against Hh
pathway
Hh pathway antibodies were validated against protein lysates
from LnCaP cells ectopically expressing Gli1 with resulting
upregulation of the key effectors of Hh signaling [30].
Negative control tissue was human wild-type fibroblasts.
Pre-cast Any kD™SDS-polyacrylamide gel (Bio-Rad,
Boston, MA, USA) was used to separate proteins. Twenty
micrograms of protein was heated for 5 min at 95°C and
mixed with 5X loading dye (100 mM Tris-GCL pH 6.8, 4%
SDS; 200 mM dithiothreitol, 0.2% bromophenol blue, and
20% glycerol). Exact volume varied in order to get 20 μg of
protein per lane. DualColor Prestained Protein Ladder (Bio-
Rad) was used for the identification of protein size. The gel
was placed into a mini-PROTEAN tetra cell system (Bio-Rad)
and run for 1 h and 30 min at 60 V in 1× Nupage MES SDS
running buffer (Life Technologies, Thermo Fisher Scientific
Inc., Waltham, MA, USA). Protein was transferred onto an
Immun-Blot™ PVDF membrane (Bio-Rad) using a Trans-
Blot SD semi-dry transfer cell (Bio-Rad) and Nupage
Transfer Buffer (Life Technologies) at ~8 V for 1 h.
Subsequently, the membrane was blocked overnight at 4 °C
in blocking solution (0.4% PBS/Tween (PBST), 5% drymilk).
The following morning, the membrane was washed five times
in PBST and then incubated for 2 h at room temperature with
the antibody of interest (1:500 anti-PTCH, 1:200 anti-SMO,
1:1000 anti-Gli1, and 1:500 anti-Gli2). The membrane was
then washed five times in PBST for 5 min, and incubated with
1:10,000 conjugated secondary anti-rabbit IgG horseradish
peroxidase (HRP) (Dako, Glostrup, Denmark) for 1 h at room
temperature. A further five washes of PBST for 5 min before
the use of an ECL™ Prime Western blotting detection system
kit (GE Healthcare, Buckinghamshire, UK). All blots were
imaged under the same conditions; signal was detected using
the ChemiDoc MP Imaging system (Bio-Rad) and ImageLab
software (Bio-Rad). Membranes were stripped of primary an-
tibody using Restore™ Western Blot Stripping Buffer
(Thermo Fisher Scientific, Inc) at 55 °C for 30 min, washed
five times for 5 min in PBST, and reprobed with 1:5000 poly-
clonal anti-β-actin antibody (Sigma-Aldrich, MO, USA) as a
loading control for each sample.
Statistical analysis
Recorded immunofluorescence signal data for each sample is
expressed as a mean ± SEM. Comparison between SC, nBCC,
and normal groups wasmade using theMann–WhitneyU test.
Critical values were identified for a p value of less than 0.05
and 0.01 and a U value less than these were considered to be
significant.
Results
Hh pathway expression was detected in all 15 SC and nBCC
tumors as demonstrated by the DAB immunostaining for
PTCH1, SMO, Gli1, and Gli2 (Fig. 1). Western blot of
LNCaP-Gli1 cells, a known hyper-expressed Hh pathway
cancer cell line, demonstrated good specificity of each anti-
body with a clear band for the appropriate-sized protein
(Fig. 2). PTCH1 expression was detected in the cytoplasm
of both nBCC and SC (Fig. 1 e and i, respectively) however,
PTCH1 expression was markedly more pronounced in SC
compared to nBCC. Similar levels of SMO were observed in
both nBCC and SC (Fig. 1f and j). Gli1 and Gli2 were detect-
ed in the cytoplasm and nuclei of both nBCC and SC (Fig. 1g,
k, h, and i, respectively). Gli1 expression was stronger in SC
compared to nBCC, whereas similar levels of Gli2 were ob-
served in both nBCC and SC.
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Fig. 1 Representative pictures of Hedgehog pathway expression in
positive control tissue (a-d), nBCC (e-h) and SC (i-l). a Breast tissue
displays PTCH1 expression in the cytoplasm of the cells (black
arrows). b SMO expression in testicular tissue, within the Leydig cells
and seminiferous tubules cells (black arrows). c Gli1 nuclear and
cytoplasmic expression in testicular tissue, particularly in the Leydig
cells and seminiferous tubules (black arrows). d Nuclear expression of
Gli2 in intestinal tissue, specifically localized to epithelial cells of the
intestinal glands. e PTCH1 expression in the cytoplasm (black arrows)
of nBCC, similar to control tissue. f Similar SMO expression in nBCC
compared to control. g Increased Gli1 nuclear expression in nBCC
compared to control tissue. h Increased Gli2 nuclear expression
compared to control tissue. i Marked PTCH1 cytoplasmic expression in
SC compared to control and nBCC. j Slight increase in staining of SMO
in the cytoplasm (black arrows) of SC in contrast to nBCC. k Increased
staining of nuclear (black arrows) and cytoplasmic Gli1 in SC compared
to nBCC, and increased cytoplasmic expression compared to control. l
Nuclear staining of GLi2 (black arrows) in SC that is similar to nBCC,
but more than control tissue. Scale bar represents 250 μm and all images
are at 200× magnification. Antibody stains for PTCH1 (a, e, i), SMO (b,
f, j), Gli1 (c, g, k) and Gli2 (d, h, l). PTCH1 Patched 1, SMO
Smoothened, Gli1 glioma-associated zinc transcription factor1, Gli2
glioma-associated zinc transcription factor2
Fig. 2 Western-blot analysis of LnCaP-Gli1 and human wild-type
fibroblasts demonstrating good specificity of each antibody with a clear
band for the appropriate sized protein (20 μg per lane, n = 3 biological
replicates). 1 = LnCaP-Gli1; 2 = Human wild-type fibroblasts. PTCH1
Patched 1, SMO Smoothened, Gli1 glioma-associated zinc transcription
factor1, Gli2 glioma-associated zinc transcription factor2
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Immunofluorescence analysis was used to better quantify
the amount of PTCH1, SMO, Gli1, and Gli2 expression in SC
and nBCC (Fig. 3). A comparison between SC tumor and
nBCC tumor was made along with physiologically activated
Hh signaling (Fig. 4). PTCH1, SMO, Gli1, and Gli2 displayed
higher levels of fluorescence in SC compared to nBCC
(P < 0.01) (Fig. 4a). PTCH1, SMO, and Gli-2 were also
expressed at higher levels in SC than physiological Hh signal-
ing (P < 0.01). nBCC had similar levels of PTCH1 and Gli2 to
physiologically activated Hh, but markedly lower expression
of SMO and Gli1 (P < 0.01). Gli1 expression is lower in both
tumors compared to normal expression; however, expression
is still higher in SC than nBCC (P < 0.01).
Comparison of stromal expression using immunofluores-
cence (Fig. 4b) showed that PTCH1, Gli1, and Gli2 weremore
highly expressed in the stroma of SC compared to nBCC
(P < 0.01). PTCH1 and Gli2 were highly upregulated in SC
stroma compared to both normal expression and nBCC
(P < 0.01). Gli1 is less expressed in SC (P < 0.05) and
nBCC (P < 0.01) compared to physiological Hh expression.
Discussion
This is the first study, as far as we are aware, that demonstrates
the expression of the canonical Hh pathway, namely PTCH1,
SMO, Gli1, and Gli2 in SC. Our results confirm that expres-
sion patterns are beyond normal reactivation levels, suggest-
ing aberrant signaling.
DAB immunostaining is good for the detection of protein,
however, quantification is highly subjective, for example, the
use of the immunoreactivity score demonstrates significant in-
terobserver variability has been shown in several studies [31,
32]. Immunofluorescence was employed to semi-quantify the
amount of protein expression in the SC tumor in order to reduce
this observer bias by computational counting along with the
removal of background noise. Nevertheless, any immunohisto-
chemistry method has many variables during processing, so
relative expression to another tumor processed in an identical
fashion is a more robust way of analyzing overall expression. In
order to do this, a known aberrant Hh pathway tumor, nBCC,
was selected for comparison [33]. Hh signaling is normally
switched off in the majority of adult tissues, however, some do
Fig. 3 Representative pictures of Hedgehog pathway expression proteins
using immunofluorescence in positive control tissue (a breast; b brain; c
testicular; d intestinal), nBCC (e-h) and SC (i-l). Secondary antibody
staining utilized AlexaFluor-568 and the color converted into black and
white using ImageJ for pictorial purposes. Scale bar represents 250 μm
and all images are at 200× magnification. Antibody stains for PTCH1 (a,
e, i), SMO (b, f, j), Gli1 (c, g, k) and Gli2 (d, h, l). PTCH1 Patched 1,
SMO Smoothened, Gli1 glioma-associated zinc transcription factor1,
Gli2 glioma-associated zinc transcription factor2
Fig. 4 Semi-quantification of antibody expression (x-axis) within a SC
tumor, nBCC tumor, control tissue and b stroma of SC, nBCC, control
tissue using fluorescence intensity (y-axis) was determined in regions of
interest as delineated by microscopy, ensuring a standardized area size
whilst containing the same number of nuclei as determined by DAPI
staining. Each tumor sample had an average of three readings. Each bar
represents mean values ± SEM taken from 15 nBCC, 15 SC and control
tissue samples for each Hh protein. *P < 0.01** P < 0.05. PTCH1
Patched 1, SMO Smoothened, Gli1 glioma-associated zinc transcription
factor1, Gli2 glioma-associated zinc transcription factor2
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transiently express Hh. These normal tissue samples represent
physiologically expressed Hh and were also used for compari-
son to determine if expression was simply re-activation or aber-
rant overexpression.
Levels of expression within SC tumor were significantly
higher than those observed in nBCC. Furthermore, these
levels were more than physiological re-activation, except for
Gli1, which was less than in normal Hh-expressing tissue. It is
estimated that up to 25% of tumors depend on the Hh pathway
activity for growth [34]. Nodular BCC is a slow-growing can-
cer that metastasizes rarely [33]. In contrast, SC is locally
aggressive, metastasizes and has a risk of mortality of up to
29% [8–10]. Thus, it is possible that the increased Hh expres-
sion seen in SC accounts for its more aggressive nature com-
pared to nBCC. The exact role of Hh expression in SC cannot
be discerned from this study alone, as Hh signaling has been
implicated in tumorigenesis, growth, progression, local inva-
sion, and metastasis [17–20].
The stroma of SC was found to express components of the
Hh pathway, and in particular, Gli2 was considerably more up-
regulated. Cancer can modify the surrounding non-malignant
tissue to facilitate local invasion [26]. Gli2 is an activator of
the Hh pathway and plays a critical role in medulloblastoma
tumorigenesis, with loss of Gli2 expression preventing the tu-
mor formation [35, 36]. Moreover, higher levels of Gli2 are
associated with a loss of the cell adhesion molecule E-
cadherin inmelanoma cell lines with increased capacity for local
invasion; higher levels correlated with the most aggressive tu-
mors [37, 38]. In contrast, knockdown models of Gli2 demon-
strated reduced tumor growth in prostatic in vivo models [39].
Hh expression as a lone stimulator is unlikely and crosstalk with
multiple pathways can occur. For example, transforming growth
factor-β (TGF-β) has been shown to promote Gli2 expression
and is involved in tumor progression and metastasis [40].
Activation of the Hh pathway in SC raises the possibility of
medical treatment for these tumors, and potentially avoiding
exenteration. Attenuation of the Hh pathway has been shown
to be successful by using SMO inhibitors, with vismodegib
presently being themost widely used compound in clinical trials
and used for locally advanced or metastatic BCC [41, 42].
Furthermore, neoadjuvant treatment with vismodegib to reduce
tumor size in BCC [43] has been successful inmaking the tumor
more amenable to surgery. Vismodegib has been trialed in a
variety of cancers, including pancreatic, ovarian cancer, breast
and prostate cancers, and other SMO inhibitors are emerging
such as sonidegib and BMS-833923 [44]. Gli antagonists have
been developed too, and this may be a more promising level to
block the pathway, especially Gli2 and could be used in combi-
nation to either block Hh at multiple levels or activated path-
ways [45]. It is possible that these agents could be efficacious in
advanced or metastatic SC and if such a neoadjuvant response
could be replicated, it may allow the preservation of sight by
averting the need for a blinding exenteration.
Limitations of the study include a small sample size, al-
though as SC is a rare tumor inWestern countries, it is difficult
to obtain high numbers. Further studies are required to identify
the role of each protein in relation to SC behavior and could
include tumorigenesis, propagation, local invasion, migration,
or metastasis.
Hedgehog pathway activation occurs in periocular SC, in
both the tumor and surrounding stromal tissue at a higher level
than nBCC, a known Hh-driven tumor. The timing for any
treatment modification of the Hh pathway would be depen-
dent on its specific role in the pathogenesis of SC, and further
studies are required to determine this.
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